Vaccinex Inc.
12
2
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
Role: collaborator
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Role: collaborator
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Role: collaborator
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Role: lead
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Role: lead
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
Role: lead
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Role: collaborator
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Role: lead
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
Role: lead
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Role: collaborator
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Role: lead
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
Role: lead
All 12 trials loaded